Skip to content

Trial Summary

This project is testing the safety, pharmacokinetics (PK, the amount of study drug in your blood), and pharmacodynamics of single intravenous doses of a new drug called EARLI-001. EARLI-001 is a method for the detection of cancers.

Acronym:

EARLi

ACTRN/NCT /ethics:

ACTRN12620001178932

Scientific title:

A Phase 1, open label, single dose, dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of EARLI-001 in subjects with locally advanced or metastatic lung cancer or subjects with metastases in the lung or liver of a primary cancer origin other than lung cancer.

Sponsor / Cooperative group:

Earli

Trial & Patient Characteristics

Cancer TypeLung & mesothelioma
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-12-14
Anticipated End Date-

Participating Hospitals

HospitalIcon Cancer Centre Adelaide
Clinical Trial CoordinatorSue Yeend
Emailsue.yeend@icon.team
Phone08 8292 2204
Principal InvestigatorDr Gonzalo Tapia Rico
Recruitment StatusRecruiting